NextCure
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 82
- Market Cap
- -
- Website
- http://www.nextcure.com
- Introduction
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
NextCure's LNCB74, a B7-H4 ADC, Enters Phase 1 Trial for Multiple Cancers
• NextCure has dosed the first patient in a Phase 1 study of LNCB74, an antibody-drug conjugate (ADC) targeting B7-H4, for various cancers.
• The study aims to evaluate the safety, tolerability, and preliminary anti-tumor activity of LNCB74 in patients with multiple cancers.
• LNCB74 received FDA clearance for its Investigational New Drug application in December 2024 and is being co-developed with LigaChem Biosciences.
• NextCure is focused on developing innovative medicines for cancer patients who have not responded to or progressed on current therapies.
FDA Approves IND Application for NextCure's B7-H4-Targeting ADC, LNCB74, for Solid Tumors
• The FDA has accepted NextCure's IND application for LNCB74, an antibody-drug conjugate (ADC) targeting B7-H4, paving the way for Phase 1 clinical trials.
• LNCB74, co-developed with LigaChem Biosciences, aims to treat multiple cancers, including breast, ovarian, and endometrial cancers, by targeting B7-H4 overexpressed in cancer cells.
• Preclinical data demonstrated LNCB74's potential with complete tumor eradication at low doses and superior anti-tumor efficacy compared to other B7-H4-targeting ADCs.
• Phase 1 trials, led by NextCure, will begin early next year, including dose escalation and expansion studies to determine safe dosing and confirm therapeutic dosage.
© Copyright 2025. All Rights Reserved by MedPath